Ligandrol LGD-4033 1 Gram
What is Ligandrol?
Ligandrol (LGD-4033) is also known as VK5211 and the name Anabolicum, was first researched by Ligand Pharmaceuticals and patented in 2009.
In 2013 the results of the first human clinical trial were published, where taking Ligandrol was found to increase muscle mass without also putting on fat, currently it is licensed to the Viking Therapeutics.
In 2018 Viking carried out a clinical trial which examined Ligandrol for people aged over 65 who were recovering from a hip fracture. Patients who took Ligandrol significantly increased their muscle mass and could walk further than patients not on the drug.
The LGD-4033 has also been examined for other conditions, including as a possible treatment for cancer-related weight loss, enlarged prostates, for patients who have a diminished function of testes and ovaries, and as a potential cure for breast cancer.